What do an eye hospital in Madurai, Tamil Nadu and Google founder Larry Page have in common? Quite simply, the future of eyecare.

In 2006, Page flew down to the south Indian temple town to stitch what was then deemed a mere “long-term working relationship” with Aravind Eye Care. Google didn’t have to do much initially. It trained doctors and other staff in IT and assisted the hospital with its distance education programme. But soon after, the two partners put their heads together to solve one of the most pressing problems in eyecare—prevention of blindness. More specifically, Aravind Eye Care, and subsequently, Sankara Nethralaya, wanted to work with Google to develop and validate deep-learning algorithms to help in detecting diabetic retinopathy—an eye condition that is the most common cause of vision loss among diabetic people.

Today, after working on 130,000 images from these hospitals with 54 American ophthalmologists, Google has an algorithm, rather a labelling tool, that grades eye images for disease detection. And no surprise, it does the task a wee bit better than humans. “Our algorithm very closely matched the performance of the American eye doctors. In the ‘F score’, which Google uses to measure its accuracy, the algorithm did just a little better than the human ophthalmologist,” said Lily Peng, a product manager at Google, during a conversation at ‘Made with AI’ in Tokyo* on Tuesday.

It’s interesting how far she has come. Just two years ago, Peng was busy dealing with health-related searches as part of the company’s search team. At that time, Google was dabbling in healthcare through applications like Google Fit and its research initiative was focused on improving ageing through its biotech venture Calico. Since Google was actively integrating artificial intelligence (AI) and machine learning into its core products then, Peng and her colleagues got started on a side project with a hypothesis.  “I, along with other folks, saw how machine learning was transforming our other core products. And we thought if we were able to detect dog breeds [through] images, maybe we could also help with medical images,” says Peng.

This was also before Google’s current CEO Sundar Pichai reoriented the company’s philosophy from a then “mobile-first” company to the current “AI-first” company. Little did Google realise that what initially began as a side project, would result in the company’s flagship AI stamp on healthcare.

Apart from Verily Life Sciences and DeepMind Health, it has acquired a few startups and is incubating fresh ones through Launchpad Studio. The search giant isn’t articulating set goals like it did with, say, driverless cars. For now, Google has two core objectives with regard to AI in healthcare. One, make a tool that makes it easier to find diseases. Two, help strengthen research across communities. While it does see a business opportunity, and according to Google, a more enterprise one at that, it is in no hurry to monetise its algorithms.

AUTHOR

Venkat Ananth

Venkat is currently in his tenth year in journalism. Prior to The Ken, he was Deputy Content Editor at Mint as part of the newspaper’s digital team. He also wrote in-depth features on the business of sport for the newspaper. His earlier assignments include Yahoo! (as a columnist) and the Hindustan Times, where he began his career. Born in Mumbai, Venkat holds a Bachelor of Mass Media (Journalism) degree from SIES College of Arts, Science and Commerce, Mumbai and a Master of Arts degree in International Studies from Goldsmiths, University of London. He currently resides in New Delhi, where he moved nearly five years ago.

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?

MOST POPULAR

Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750

Subscribe
 

Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750

Subscribe
 

Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500

Subscribe
MOST POPULAR

Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120

Subscribe
 

Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50

Subscribe
 

Single Story

Instant access to this story for a year along with comment privileges.

$ 20

Subscribe

Questions?

What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at [email protected] detailing the error or queries.